Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esmethadone - Relmada Therapeutics

Next Previous
Drug Profile

Esmethadone - Relmada Therapeutics

Alternative Names: +-Methadone - Relmada Therapeutics; 6S-Methadone - Relmada Therapeutics; d Methadone - Relmada Therapeutics; Dextromethadone - Relmada Therapeutics; Esmethadone hydrochloride - Relmada Therapeutics; REL 1017; S-(+)-methadone; S-Methadone - Relmada Therapeutics

Latest Information Update: 13 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University
  • Developer Relmada Therapeutics
  • Class Analgesics; Antidepressants; Antipsychotics; Drug withdrawal therapies; Eye disorder therapies; Ketones; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Discontinued Eye disorders; Mitochondrial disorders; Neuropathic pain; Rett syndrome

Most Recent Events

  • 09 Dec 2024 Relmada Therapeutics terminates the phase III Reliance II and Relight trial in Major depressive disorder (Adjunctive therapy) in USA (PO) due to data monitoring committee (DMC) evaluation (NCT04855747) (NCT06011577)
  • 18 Jun 2024 Efficacy and adverse events data from phase III RELIANCE I trial in major depressive disorder released by Relmada Therapeutics
  • 15 Jan 2024 Discontinued - Phase-I for Neuropathic pain (In volunteers) in Canada (PO) before January 2024 (Relmada Therapeutics pipeline, January 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top